MARKET

COCP

COCP

Cocrystal Pharma Inc
NASDAQ
1.020
-0.015
-1.45%
After Hours: 1.020 0 0.00% 16:04 12/05 EST
OPEN
1.020
PREV CLOSE
1.035
HIGH
1.040
LOW
1.010
VOLUME
19.29K
TURNOVER
--
52 WEEK HIGH
3.260
52 WEEK LOW
0.9000
MARKET CAP
14.06M
P/E (TTM)
-1.0902
1D
5D
1M
3M
1Y
5Y
1D
Cocrystal Pharma to Present at Emerging Growth Conference
TipRanks · 4d ago
Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development
Reuters · 4d ago
Weekly Report: what happened at COCP last week (1124-1128)?
Weekly Report · 4d ago
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares
Reuters · 11/28 14:00
Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares
Reuters · 11/26 01:17
Weekly Report: what happened at COCP last week (1117-1121)?
Weekly Report · 11/24 09:30
Weekly Report: what happened at COCP last week (1110-1114)?
Weekly Report · 11/17 09:30
Cocrystal Pharma Receives FDA Clearance and NIH Grant to Advance Norovirus and Influenza Programs
Reuters · 11/14 13:31
More
About COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Webull offers Cocrystal Pharma Inc stock information, including NASDAQ: COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COCP stock methods without spending real money on the virtual paper trading platform.